Search

Your search keyword '"Chen, Zhenping"' showing total 506 results
Start Over Author "Chen, Zhenping" Language english
506 results on '"Chen, Zhenping"'

23. Longitudinal study of 2 patients with cyclic thrombocytopenia, STAT3 and MPL mutations

Author

Zhang, Haiyu, Chien, May, Hou, Yu, Shomali, William, Brar, Rondeep S., Ho, Chandler, Han, Panpan, Xu, Danfei, Zhang, Bing M., Guo, Xiangqian, Tolentino, Lorna L., Wu, Nancy C., Tsai, Albert G., Jin, Jing, Witteles, Wesley H., Chen, Zhenping, Abidi, Parveen, Jangam, Diwash, Krieger, Madison S., Craig, Morgan, Bussel, James B., Gotlib, Jason R., and Zehnder, James L.

Published
2023
Full Text
View/download PDF

31. Significant reduction in hemarthrosis in boys with severe hemophilia A: The China hemophilia individualized low‐dose secondary prophylaxis study

Author

Wu, Runhui, Li, Xiaojing, Yao, Wanru, Zhang, Qing, Zhou, Min, Zhang, Ningning, Yang, Sheng, Chen, Zhenping, Wang, Yan, Kuang, Yangying, Tang, Ling, Zhen, Yingzi, Abad, Audrey, Doria, Andrea S., Hilliard, Pamela, Ignas, Danial M., Mathew, Prasad, Stephens, Derek, Blanchette, Victor S., and Luke, Koon‐Hung

Published
2021
Full Text
View/download PDF

37. The influence of dead space in blood sampling needle on FVIII level and pharmacokinetic profiles in children with hemophilia.

Author

Zhen, Yingzi, Ai, Di, Huang, Kun, Li, Gang, Chen, Zhenping, and Wu, Runhui

Subjects
PARTIAL thromboplastin time, VACUUM tubes, BLOOD coagulation factor VIII, BLOOD sampling, HEMOPHILIA
Abstract

Objective: To investigate the influence of the dead space in disposable blood sampling needle on activated partial thromboplastin time (APTT), FVIII level and pharmacokinetic (PK) profiles in children with hemophilia. Methods: Children (<18 years) with severe hemophilia A were enrolled. After three days' washout-period, blood samples were collected at pre-dose, 1 h, 3 h, 9 h, 24 h and 48 h post-infusion. At each timepoint, two 2 mL vacuum tubes with 3.2% trisodium citrate were used. The first tube was signed as 'non-standard' (NS) and the second tube was signed as 'standard' (S). FVIII activities were evaluated by one-stage assay. WAPPS-Hemo was used to generate PK profiles like half-life time (t1/2), clearance (CL), trough level and time to 1, 2 and 5IU/dL after a dose of 50 ± 10IU/dL. The FVIII activities at 9 h and 24 h post-infusion were put into WAPPS and thus brought four combinations by true or biased FVIII level that used. Result: Compared with standard-collected blood samples, prolonged APTT results (P-values < 0.01) and decreased FVIII activity (P-values < 0.05) were revealed in those non-standard blood samples. The corresponding bias was in positive relation to both APTT-S (r = 0.44, P < 0.0001) and FVIII-S level(r = 0.68, P < 0.001). The FVIII bias percentage got larger as FVIII-S level reduced (r = −0.24, P < 0.01). During the four combinations of FVIII activity at 9 h and 24 h, statistically longer t1/2, lower CL and longer time to 1, 2 or 5IU/dL were observed in 9H-S&24H-S group and 9H-NS&24H-S group. Conclusion: While using vacuum tubes for clotting indicators and PK profiles, the dead space of blood sampling needle should be eliminated in advance. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

38. Real‐world use of emicizumab in Chinese children with hemophilia A: Retrospective data from a comprehensive care center.

Author

Mao, Qianqian, Chen, Zhenping, Liu, Guoqing, Li, Gang, Zhen, Yingzi, Cheng, Xiaoling, Li, Zekun, Yao, Wanru, Ai, Di, Li, Zhengping, Wang, Nan, Poon, Man‐Chiu, and Wu, Runhui

Subjects
CHINESE people, BLOOD coagulation factor VIII, EMICIZUMAB, HEMOPHILIA, FACTOR analysis
Abstract

Importance: Emicizumab (EMI) is efficacious and safe for hemophilia A (HA) prophylaxis. However, its high cost poses a challenge in China. Objective: To explore the possibility of using reduced‐dosage EMI in Chinese HA children. Methods: We conducted a retrospective study for HA children in our Comprehensive Care Center. Data were collected pre‐ and post‐EMI treatment to evaluate bleeding rates. Laboratory analyses included factor VIII (FVIII)‐like activity and EMI concentration measurements. Results: Thirty‐four HA children receiving EMI prophylaxis for a median (range) 24.5 (2.5–47.9) months by June 2023. Of these, 25 (73.5%) were under 3 years of age, 26 (76.5%) had severe hemophilia and 12 (35.3%) were minimally treated or previously untreated patients. Thirty‐one (91.2%) of the 34 patients received reduced‐dosage EMI for economic reasons. EMI concentration and FVIII‐like activity measured showed a strong correlation. Overall, while on EMI, their annual treated bleeding rate (ATBR) and annual bleeding rate (ABR) decreased significantly (2–0) while their zero‐bleeding rate (ZBR) increased significantly (11.5%–65.4%). After 6 months of EMI, there was no significant difference in ATBR and ABR among various maintenance dosages. However, ZBR was significantly lower in dosages under 4 mg/kg (P = 0.0156). Receiver operator characteristic curves suggested the following cutoff values for zero bleeding: EMI 4‐weekly maintenance dosage 3.8 mg/kg, EMI concentration 48.1 μg/mL, and FVIII‐like activity 15.4 IU/dL. Interpretation: We showed EMI effectively prevented bleeding even at reduced dosages. However, the bleeding risk may be higher with EMI 4‐weekly maintenance dosage <3.8 mg/kg, EMI concentration <48.1 μg/mL, and FVIII‐like activity <15.4 IU/dL for zero bleeding. It is important that dosage reduction be done rationally. Dosage tailoring is possible. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

39. Exploratory study on the individualized application of eltrombopag in paediatric immune thrombocytopenia guided by therapeutic drug monitoring.

Author

Dong, Shuyue, Wang, Zhifa, Wang, Nan, Ma, Jingyao, Meng, Jinxi, Chen, Zhenping, Wu, Runhui, and Cheng, Xiaoling

Subjects
DRUG side effects, DRUG monitoring, IDIOPATHIC thrombocytopenic purpura, PLATELET count, ELTROMBOPAG
Abstract

Summary: There are variations in individual eltrombopag concentrations that may impact efficacy and adverse drug reactions (ADRs) in paediatric immune thrombocytopenia (ITP). To solve this problem, we tailored the eltrombopag dosage refer to concentration, then followed up to assess concentration value in paediatric ITP. This is a single‐centre, prospective, observational study. The eltrombopag dosage was adjusted, and children were divided into three groups: the maintenance, discontinuation, and increase groups. Concentration and other data were compared to explore concentration value in guiding the individualized treatment of paediatric ITP. Thirty‐nine patients were enrolled, including 23 in the maintenance group, 3 in the discontinued group and 13 in the increase group. 3 patients discontinued eltrombopag due to ADRs, which was significantly higher than patients in the maintenance group (t = 3.606, p = 0.001). In all, 13 patients increased their dosage due to poor response, whose concentration and platelet count were significantly lower than patients in the maintenance group (t = 2.461, p = 0.019; t = 4.633, p < 0.001). Two months after the increase, the number of patients reaching CR and R respectively increased by 2 and 3, while the median platelet count was significantly raised (Z = −2.411, p = 0.016). Concentration could be used as a reference index for the individualized treatment of eltrombopag in paediatric ITP. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

48. Power charging management strategy for electric vehicles based on a Stackelberg game

Author

Fei Zhaoan, Fu Baochuan, Xi Xuefeng, Wu Zhengtian, Chen Zhenping, and Xu Xinyin

Subjects
power charging management strategy, electric vehicles charging efficiency, power grid, EV users, charging control strategy, 1‐N‐type Stackelberg game, Transportation engineering, TA1001-1280, Electronic computers. Computer science, QA75.5-76.95
Abstract

Increasing electric vehicles (EV) charging efficiency and reducing charging cost are important issues of EVs power management and key factor that affect the spread of EVs. Researching the competitive relationship between power grids and EV users is the key to solving this problem. Therefore, the authors propose a charging control strategy that is based on a 1‐N‐type Stackelberg game. In the game, power grid, retailers, and users are all able to do power decision making. Thus, the charging strategy here can flexibly meet different demands of power grid, retailers, and users. The equilibrium of the game model is solved by the inverse induction method. The benefits are compared by simulation, by the disordered charging process, and by charging control methods based on static time‐sharing electricity prices. The influence of the parameters on the charging process in the game model is analysed, and the feasibility of the proposed method is verified. Results show that load peak is reduced by 34.9% while users' charging costs are reduced by 25.1%. The approaches they proposed can effectively solve the competition between the two.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results